ClinicalTrials.gg
RecruitingNCT06681428Updated Feb 10, 2025

Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers

An interventional study of Allograft in Diabetic Foot Ulcer (DFU) and Chronic Foot Ulcers, sponsored by Tides Medical. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-10.

Sponsored by Tides Medical · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 381 studies in Diabetic Foot with a site in United States — 66 open to participants now, 84 under way, 3 of them phase 3. Diabetic Foot · United States.

Planned enrollment
38th of 322
240 · median 60
Started
2024
with 32 others
No phase
186 of 381
38 open now
Primary completion
2026-11
later than 40 of 83 live
Registered
336th of 381
by date

Among the 381 studies in Diabetic Foot with a site in United States, this one is the 38th largest by planned enrollment of the 322 interventional ones that give a count, is one of 33 that started in 2024, is one of 186 with no phase, reaches primary completion later than 40 of the 83 other live ones, and was the 336th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

66 of the 381 studies in Diabetic Foot with a site in United States are open now. Recruiting first, the newest first:

61 more — sign in →

All 66 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 381 studies in Diabetic Foot with a site in United States, or all of them as a file.
02

Study summary

The purpose of this clinical investigation is to evaluate the safety and efficacy of Amnion/Chorion/Amnion allograft , Amnion/Chorion allograft, and/or Amnion/Amnion allograft, plus Standard of Care (SOC) each versus SOC alone in the treatment of chronic non-healing diabetic foot ulcers (DFU) after 12 weeks of treatment.

03

Conditions studied

  • Diabetic Foot Ulcer (DFU)
  • Chronic Foot Ulcers

Keywords

  • Amnion
  • Chorion
  • Amnion Amnion Graft
  • Amnion Chorion Amnion Grafts
  • Amnion Chorion Graft
  • Diabetes Mellitus
  • Glucose Metabolism Disorders
  • Metabolic Diseases
  • Endocrine System Diseases
  • Pathologic Processes
  • Ulcer
  • Skin Ulcer
  • Chronic Ulcer
  • Chronic Foot Ulcer
  • Diabetic Angiopathies
  • Diabetes Type 2
  • Diabetes Type II
  • Leg Ulcer
  • Placental-Based Allografts
  • Human Placental-Based Skin Grafts
  • Skin Wound Covering
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Potential subjects are required to meet all of the following criteria for enrollment into the study.

  1. At least 18 years old, inclusive.
  2. Presence of a DFU, Wagner Grade 1, extending through the dermis provided it is below the medial aspect of the malleolus.
  3. The index ulcer (ulcer to be evaluated in the study) will be the largest ulcer if two or more DFUs are present with the same Wagner grade and will be the only one evaluated in the study. If other ulcerations are present on the same foot, they must be more than 2 cm distant from the index ulcer.
  4. Index ulcer has been present for greater than 4 weeks prior to SV1 and less than 1 year, as of the date the subject consents for study.
  5. Index ulcer is a minimum of 1.0 cm2 and a maximum of 25 cm2 at SV1 and TV1.
  6. Within 3 months of SV1, adequate circulation to the affected foot as documented by a dorsal transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg, or an Ankle Branchial Index (ABI) between 0.7 and 1.3 using the affected study extremity. As an alternative, arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle or a TBI (Toe Brachial Index) of > 0.6 is acceptable.
  7. The target ulcer has been offloaded for at least 14 days, prior to TV1.
  8. Females of must be willing to use acceptable methods of (birth control pills, barriers or abstinence) during the course of the study and undergo pregnancy tests.
  9. Subject understands and is willing to participate in the clinical study and can comply with weekly visits.
  10. Subjects must have read and signed the IRB approved ICF before screening procedures are performed.

Exclusion criteria

Exclusion Criteria:

Potential subjects meeting any of the following criteria will be excluded from enrollment and subsequent treatment.

  1. Index ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes
  2. Index ulcer, in the opinion of the investigator, is suspicious for cancer and should undergo an ulcer to rule out a carcinoma of the ulcer
  3. Index ulcer is infected
  4. Subjects with a history of more than two weeks of treatment with immune-suppressants (including systemic >10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within 1-month prior to first SV1, or who receive such medications during the screening period or who are anticipated to require such medications during the course of the study
  5. Subjects on any drug(s), Investigational products, or therapeutic device(s) within 30 days preceding SV1
  6. History of radiation at the ulcer site (regardless of time since last radiation treatment)
  7. Index ulcer has been previously treated or will need to be treated with any prohibited therapies
  8. Subjects with a previous diagnosis of or
  9. Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment
  10. Osteomyelitis or bone infection of the affected foot as verified by x-ray within 30 days prior to the first screening visit. (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision)
  11. Subject is pregnant or breast-feeding
  12. Presence of diabetes with poor metabolic control as documented with an >12.0 within last 90 days
  13. Subjects with end stage renal disease as evidenced by a serum creatinine ≥3.0 mg/dL within 6 months of enrollment
  14. Presence of acute Charcot Neuroarthropathy to the affected limb
  15. Index ulcer that has reduced in area by 30% or more after 14 days of SOC from SV1 to the TV1/Randomization visit
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    "Amnion/Chorion/Amnion" common/general allograft configuration

    Topical application of placental allograft on to surface of open chronic diabetic foot ulcer using a tri-layer dehydrated amniotic membrane allograft for the treatment of DFUs. Human amniotic membrane is a thin collagenous membrane derived from the submucosa of the placenta, the organ that connects the developing fetus to the mother's uterus. A human amniotic membrane consists of multiple layers including epithelial cells, a basement membrane, and a stromal matrix which provides a natural scaffold that allows cellular attachment or infiltration and growth factor storage.

    Other: Allograft

  • No intervention
    Standard of Care

    Standard of Care (SOC) for open chronic diabetic foot ulcer using a calcium alginate dressing and will have a silicone non-adherent dressing (MepitelTM or equivalent), a padded 3-layer dressing comprised of 4x4 gauze pads, soft roll, compressive wrap and Coban (Threeflex 3-layer or equivalent) applied. Offloading of the DFU (removable offloading boot or total contact casting \[TCC\] if the subject's foot is too large for a removable offloading boot), appropriate sharp or surgical debridement, and infection management. Graft provides a protective cover and supports the body's wound healing processes. This allograft is supplied sterile and not intended to be removed.

  • Other
    "Amnion/Chorion" common/general allograft configuration

    Topical application of placental allograft on to surface of open chronic diabetic foot ulcer using a dehydrated human amniotic membrane allograft comprised of a tri-layer membrane (amnion/intermediate layer/chorion) which provides a natural scaffold that allows cellular attachment and infiltration. Human amniotic membrane is a thin collagenous membrane derived from the submucosa of the placenta. A human amniotic membrane consists of multiple layers including epithelial cells, a basement membrane, and a stromal matrix. Graft provides a protective cover and supports the body's wound healing processes. This allograft is supplied sterile and not intended to be removed.

    Other: Allograft

  • Other
    "Amnion/Amnion" common/general allograft configuration

    Topical application of placental allograft on to surface of open chronic diabetic foot ulcer using a dual layer dehydrated human amniotic membrane allograft. Human amniotic membrane is a thin collagenous membrane derived from the submucosa of the placenta, the organ that connects the developing fetus to the mother's uterus. A human amniotic membrane consists of multiple layers including epithelial cells, a basement membrane, and a stromal matrix which provides a natural scaffold that allows cellular attachment or infiltration and growth factor storage. This allograft provides a protective cover and supports the body's wound healing process. This allograft is supplied sterile and not intended to be removed.

    Other: Allograft

Interventions

  • OtherAllograft

    Placental-based Allografts

06

What researchers measure

Primary outcomes

  1. Percentage of DFUs healed at 12 weeks

    Percentage of index ulcers (the ulcers being treated in the study) healed at 12 weeks

    Time frame: 12 Weeks

Secondary outcomes

  1. Total time to DFU wound closure

    Length of time to complete wound closure of the indexed DFU

    Time frame: 12 Weeks

  2. Percentage of Wound Area Reduction over time of study

    Percentage area reduction by surface area for each indexed wound during the clinical investigation

    Time frame: 12 Weeks

  3. Change in perceived patient wound pain levels over time.

    Change in patient pain levels during the clinical investigation at the wound site using the pain assessment by questionnaire. The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').

    Time frame: 12 weeks

Other outcomes

  1. Cost of Treatment to Closure Diabetic Foot Ulcer Wound in Study

    Following costs to treat and closure diabetic foot ulcers in investigational study arms

    Time frame: 12 Weeks

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Nov 2026, 24 months after the start.

Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 24 months is close to that.

Counting every sponsor, half of 347 studies reached it within 22 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Nov 8, 2024
StartActual
Nov 14, 2024
Primary completionEst.
Nov 18, 2026
CompletionEst.
Nov 18, 2026
Last update
Feb 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06681428
Lead sponsor
Tides Medical
Collaborators
Professional Education and Research Institute
Responsible party
Sponsor
First posted
Nov 8, 2024
Start date
Nov 14, 2024
Primary completion
Nov 18, 2026 (estimated)
Completion
Nov 18, 2026 (estimated)
Last update
Feb 10, 2025

Study contacts

Frank Burrows III, MBA, EMT, BCMAS, CWCA
Contact
FBurrows@tidesmedical.com
888-494-4441
Mora Melican, PH.D.
Contact
MMelican@tidesmedical.com
888-494-4441
David G Armstrong, DPM, MD, PhD
study chair · Keck School of Medicine of USC
Frank Burrows, MBA, EMT, BCMAS, CWCA
study director · Tides Medical

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion